Pharma Powerhouse Ignites: Nifty Pharma Soars 1.1% in Stellar Rally!

Sector Surge Drivers

The pharma benchmark outperformed broader markets like Nifty 50 (up 0.37% pre-open) and IT (1%), fueled by positive US generic drug approvals and strong Q3 anticipation. Rupee climbing past 90/USD enhances competitiveness, while steady bond yields at 6.576% support funding.

Key Highlights

Index Performance: .NIPHARM up 1.1%, breaching 20,500 levels with high volumes signaling bullish conviction.

Top Performers: Sun Pharma +1.5%, Dr. Reddy's +1.3%, Cipla +1.0%; driven by US filings and CDMO deals.

Key Catalysts: INR strength cuts import costs; fresh export orders worth $500 mn reported; API price stability aids profitability.

Technical Signals: Breakout above 50-DMA; RSI at 65 indicates sustained upside toward 21,000 resistance.

Forward Momentum

Pharma's export-led growth eyes 15% FY26 revenue rise, with focus on biosimilars and specialty drugs amid global supply shifts.

Sources: NSE Real-Time Data, Moneycontrol Sector Updates, Economic Times Pharma Desk.